The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Corral, L. G.
Right arrow Articles by Kaplan, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Corral, L. G.
Right arrow Articles by Kaplan, G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*THALIDOMIDE
The Journal of Immunology, 1999, 163: 380-386.
Copyright © 1999 by The American Association of Immunologists

Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-{alpha}1

Laura G. Corral2,*, Patrick A. J. Haslett{dagger}, George W. Muller*, Roger Chen*, Lu-Min Wong*, Christopher J. Ocampo{dagger}, Rebecca T. Patterson*, David I. Stirling* and Gilla Kaplan{dagger}

* Celgene Corporation, Warren, NJ 07059; and {dagger} Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY 10021

TNF-{alpha} mediates both protective and detrimental manifestations of the host immune response. Our previous work has shown thalidomide to be a relatively selective inhibitor of TNF-{alpha} production in vivo and in vitro. Additionally, we have recently reported that thalidomide exerts a costimulatory effect on T cell responses. To develop thalidomide analogues with increased anti-TNF-{alpha} activity and reduced or absent toxicities, novel TNF-{alpha} inhibitors were designed and synthesized. When a selected group of these compounds was examined for their immunomodulatory activities, different patterns of cytokine modulation were revealed. The tested compounds segregated into two distinct classes: one class of compounds, shown to be potent phosphodiesterase 4 inhibitors, inhibited TNF-{alpha} production, increased IL-10 production by LPS-induced PBMC, and had little effect on T cell activation; the other class of compounds, similar to thalidomide, were not phosphodiesterase 4 inhibitors and markedly stimulated T cell proliferation and IL-2 and IFN-{gamma} production. These compounds inhibited TNF-{alpha}, IL-1ß, and IL-6 and greatly increased IL-10 production by LPS-induced PBMC. Similar to thalidomide, the effect of these agents on IL-12 production was dichotomous; IL-12 was inhibited when PBMC were stimulated with LPS but increased when cells were stimulated by cross-linking the TCR. The latter effect was associated with increased T cell CD40 ligand expression. The distinct immunomodulatory activities of these classes of thalidomide analogues may potentially allow them to be used in the clinic for the treatment of different immunopathological disorders.




This article has been cited by other articles:


Home page
 BloodHome page
M. Wang, M. A. Dimopoulos, C. Chen, M. T. Cibeira, M. Attal, A. Spencer, S. V. Rajkumar, Z. Yu, M. Olesnyckyj, J. B. Zeldis, et al.
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Blood, December 1, 2008; 112(12): 4445 - 4451.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Lafaras, E. Mandala, E. Verrou, D. Platogiannis, N. Barbetakis, T. Bischiniotis, and K. Zervas
Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study
Ann. Onc., October 1, 2008; 19(10): 1765 - 1769.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Ferrajoli, B.-N. Lee, E. J. Schlette, S. M. O'Brien, H. Gao, S. Wen, W. G. Wierda, Z. Estrov, S. Faderl, E. N. Cohen, et al.
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
Blood, June 1, 2008; 111(11): 5291 - 5297.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Chanan-Khan and B. D. Cheson
Lenalidomide for the Treatment of B-Cell Malignancies
J. Clin. Oncol., March 20, 2008; 26(9): 1544 - 1552.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Blansfield, D. Caragacianu, H. R. Alexander III, M. A. Tangrea, S. Y. Morita, D. Lorang, P. Schafer, G. Muller, D. Stirling, R. E. Royal, et al.
Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy
Clin. Cancer Res., January 1, 2008; 14(1): 270 - 280.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Raza, J. A. Reeves, E. J. Feldman, G. W. Dewald, J. M. Bennett, H. J. Deeg, L. Dreisbach, C. A. Schiffer, R. M. Stone, P. L. Greenberg, et al.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Blood, January 1, 2008; 111(1): 86 - 93.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Pellagatti, M. Jadersten, A.-M. Forsblom, H. Cattan, B. Christensson, E. K. Emanuelsson, M. Merup, L. Nilsson, J. Samuelsson, B. Sander, et al.
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients
PNAS, July 3, 2007; 104(27): 11406 - 11411.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Tabata, R. Tabata, Y. Kadokawa, S. Hisamori, M. Takahashi, M. Mishima, T. Nakano, and H. Kubo
Thalidomide Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice
J. Immunol., July 1, 2007; 179(1): 708 - 714.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. Thornburg, R. Abonour, P. Smith, K. Knox, and H. L. Twigg III
Hypersensitivity Pneumonitis-Like Syndrome Associated With the Use of Lenalidomide
Chest, May 1, 2007; 131(5): 1572 - 1574.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Verhelle, L. G. Corral, K. Wong, J. H. Mueller, L. Moutouh-de Parseval, K. Jensen-Pergakes, P. H. Schafer, R. Chen, E. Glezer, G. D. Ferguson, et al.
Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells
Cancer Res., January 15, 2007; 67(2): 746 - 755.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Tefferi, J. Cortes, S. Verstovsek, R. A. Mesa, D. Thomas, T. L. Lasho, W. J. Hogan, M. R. Litzow, J. B. Allred, D. Jones, et al.
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Blood, August 15, 2006; 108(4): 1158 - 1164.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. Kiaei, S. Petri, K. Kipiani, G. Gardian, D.-K. Choi, J. Chen, N. Y. Calingasan, P. Schafer, G. W. Muller, C. Stewart, et al.
Thalidomide and Lenalidomide Extend Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis
J. Neurosci., March 1, 2006; 26(9): 2467 - 2473.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P.-K. Li, B. Pandit, D. L. Sackett, Z. Hu, J. Zink, J. Zhi, D. Freeman, R. W. Robey, K. Werbovetz, A. Lewis, et al.
A thalidomide analogue with in vitro antiproliferative, antimitotic, and microtubule-stabilizing activities.
Mol. Cancer Ther., February 1, 2006; 5(2): 450 - 456.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
L. Gullestad, T. Ueland, J. G. Fjeld, E. Holt, T. Gundersen, K. Breivik, M. Folling, A. Hodt, R. Skardal, J. Kjekshus, et al.
Effect of Thalidomide on Cardiac Remodeling in Chronic Heart Failure: Results of a Double-Blind, Placebo-Controlled Study
Circulation, November 29, 2005; 112(22): 3408 - 3414.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Tefferi
Pathogenesis of Myelofibrosis With Myeloid Metaplasia
J. Clin. Oncol., November 20, 2005; 23(33): 8520 - 8530.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. J. Hernandez-Ilizaliturri, N. Reddy, B. Holkova, E. Ottman, and M. S. Czuczman
Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model
Clin. Cancer Res., August 15, 2005; 11(16): 5984 - 5992.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Vacca, C. Scavelli, V. Montefusco, G. Di Pietro, A. Neri, M. Mattioli, S. Bicciato, B. Nico, D. Ribatti, F. Dammacco, et al.
Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma
J. Clin. Oncol., August 10, 2005; 23(23): 5334 - 5346.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. List, S. Kurtin, D. J. Roe, A. Buresh, D. Mahadevan, D. Fuchs, L. Rimsza, R. Heaton, R. Knight, and J. B. Zeldis
Efficacy of Lenalidomide in Myelodysplastic Syndromes
N. Engl. J. Med., February 10, 2005; 352(6): 549 - 557.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Kaufmann, M. Raderer, S. Wohrer, A. Puspok, A. Bankier, C. Zielinski, A. Chott, and J. Drach
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
Blood, October 15, 2004; 104(8): 2269 - 2271.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S.A. Schey, P. Fields, J.B. Bartlett, I.A. Clarke, G. Ashan, R.D. Knight, M. Streetly, and A.G. Dalgleish
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
J. Clin. Oncol., August 15, 2004; 22(16): 3269 - 3276.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood, August 1, 2004; 104(3): 607 - 618.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin. Proc.Home page
S. V. Rajkumar
Thalidomide: Tragic Past and Promising Future
Mayo Clin. Proc., July 1, 2004; 79(7): 899 - 903.
[PDF]

Home page
 BloodHome page
R. LeBlanc, T. Hideshima, L. P. Catley, R. Shringarpure, R. Burger, N. Mitsiades, C. Mitsiades, P. Cheema, D. Chauhan, P. G. Richardson, et al.
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
Blood, March 1, 2004; 103(5): 1787 - 1790.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Gee, S. Makonnen, K. al-Kofahi, B. Roysam, F. Payvandi, H.-W. Man, G. W. Muller, and W. M. F. Lee
Selective Cytokine Inhibitory Drugs with Enhanced Antiangiogenic Activity Control Tumor Growth through Vascular Inhibition
Cancer Res., December 1, 2003; 63(23): 8073 - 8078.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Dimopoulos, A. Anagnostopoulos, and D. Weber
Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives
J. Clin. Oncol., December 1, 2003; 21(23): 4444 - 4454.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. H. Schafer, A. K. Gandhi, M. A. Loveland, R. S. Chen, H.-W. Man, P. P. M. Schnetkamp, G. Wolbring, S. Govinda, L. G. Corral, F. Payvandi, et al.
Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1222 - 1232.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Med. Inform. Assoc.Home page
M. Weeber, R. Vos, H. Klein, L. T.W. de Jong-van den Berg, A. R. Aronson, and G. Molema
Generating Hypotheses by Discovering Implicit Associations in the Literature: A Case Report of a Search for New Potential Therapeutic Uses for Thalidomide
J. Am. Med. Inform. Assoc., May 1, 2003; 10(3): 252 - 259.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
J N Gordon and P M Goggin
Thalidomide and its derivatives: emerging from the wilderness
Postgrad. Med. J., March 1, 2003; 79(929): 127 - 132.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. B. Marriott, I. A. Clarke, A. Czajka, K. Dredge, K. Childs, H.-W. Man, P. Schafer, S. Govinda, G. W. Muller, D. I. Stirling, et al.
A Novel Subclass of Thalidomide Analogue with Anti-Solid Tumor Activity in Which Caspase-dependent Apoptosis is Associated with Altered Expression of bcl-2 Family Proteins
Cancer Res., February 1, 2003; 63(3): 593 - 599.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
G. Mufti, A. F. List, S. D. Gore, and A. Y.L. Ho
Myelodysplastic Syndrome
Hematology, January 1, 2003; 2003(1): 176 - 199.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. G. Richardson, R. L. Schlossman, E. Weller, T. Hideshima, C. Mitsiades, F. Davies, R. LeBlanc, L. P. Catley, D. Doss, K. Kelly, et al.
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
Blood, October 16, 2002; 100(9): 3063 - 3067.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. P. Baughman, M. A. Judson, A. S. Teirstein, D. R. Moller, and E. E. Lower
Thalidomide for Chronic Sarcoidosis*
Chest, July 1, 2002; 122(1): 227 - 232.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Tsenova, B. Mangaliso, G. Muller, Y. Chen, V. H. Freedman, D. Stirling, and G. Kaplan
Use of IMiD3, a Thalidomide Analog, as an Adjunct to Therapy for Experimental Tuberculous Meningitis
Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1887 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Mitsiades, C. S. Mitsiades, V. Poulaki, D. Chauhan, P. G. Richardson, T. Hideshima, N. C. Munshi, S. P. Treon, and K. C. Anderson
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
Blood, May 29, 2002; 99(12): 4525 - 4530.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Dredge, J. B. Marriott, S. M. Todryk, G. W. Muller, R. Chen, D. I. Stirling, and A. G. Dalgleish
Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity
J. Immunol., May 15, 2002; 168(10): 4914 - 4919.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
S J H van Deventer
Small therapeutic molecules for the treatment of inflammatory bowel disease
Gut, May 1, 2002; 50(90003): iii47 - 53.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. A. Hussein
Nontraditional Cytotoxic Therapies for Relapsed/Refractory Multiple Myeloma
Oncologist, April 1, 2002; 7(90001): 20 - 29.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. F. List
New Approaches to the Treatment of Myelodysplasia
Oncologist, April 1, 2002; 7(90001): 39 - 49.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Majumdar, B. Lamothe, and B. B. Aggarwal
Thalidomide Suppresses NF-{kappa}B Activation Induced by TNF and H2O2, But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester
J. Immunol., March 15, 2002; 168(6): 2644 - 2651.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
A Wozniacka, A Carter, and D P Mccauliffe
Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit
Lupus, February 1, 2002; 11(2): 71 - 81.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Neben, T. Moehler, G. Egerer, A. Kraemer, J. Hillengass, A. Benner, A. D. Ho, and H. Goldschmidt
High Plasma Basic Fibroblast Growth Factor Concentration Is Associated with Response to Thalidomide in Progressive Multiple Myeloma
Clin. Cancer Res., September 1, 2001; 7(9): 2675 - 2681.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Barlogie, R. Desikan, P. Eddlemon, T. Spencer, J. Zeldis, N. Munshi, A. Badros, M. Zangari, E. Anaissie, J. Epstein, et al.
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
Blood, July 15, 2001; 98(2): 492 - 494.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. E. Davies, N. Raje, T. Hideshima, S. Lentzsch, G. Young, Y.-T. Tai, B. Lin, K. Podar, D. Gupta, D. Chauhan, et al.
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
Blood, July 1, 2001; 98(1): 210 - 216.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
W. S. Dalton, P. L. Bergsagel, W. M. Kuehl, K. C. Anderson, and J. L. Harousseau
Multiple Myeloma
Hematology, January 1, 2001; 2001(1): 157 - 177.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology, January 1, 2001; 2001(1): 443 - 462.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Hideshima, D. Chauhan, Y. Shima, N. Raje, F. E. Davies, Y.-T. Tai, S. P. Treon, B. Lin, R. L. Schlossman, P. Richardson, et al.
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
Blood, November 1, 2000; 96(9): 2943 - 2950.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Verbon, N. P. Juffermans, P. Speelman, S. J. H. van Deventer, I. J. M. ten Berge, H.-J. Guchelaar, and T. van der Poll
A Single Oral Dose of Thalidomide Enhances the Capacity of Lymphocytes to Secrete Gamma Interferon in Healthy Humans
Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2286 - 2290.
[Abstract] [Full Text]

Home page
 ASH Education BookHome page
K. C. Anderson, R. A. Kyle, W. S. Dalton, T. Landowski, K. Shain, R. Jove, L. Hazlehurst, and J. Berenson
Multiple Myeloma: New Insights and Therapeutic Approaches
Hematology, January 1, 2000; 2000(1): 147 - 165.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
N. Raje and K. Anderson
Thalidomide -- A Revival Story
N. Engl. J. Med., November 18, 1999; 341(21): 1606 - 1609.
[Full Text]

Home page
 J. Biol. Chem.Home page
J. A. Keifer, D. C. Guttridge, B. P. Ashburner, and A. S. Baldwin Jr.
Inhibition of NF-kappa B Activity by Thalidomide through Suppression of Ikappa B Kinase Activity
J. Biol. Chem., June 15, 2001; 276(25): 22382 - 22387.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.